logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2019 – The addition of daratumumab results in a robust clinical benefit in transplant-eligible newly diagnosed multiple myeloma patients

Part 1 CASSIOPEIA trial results suggest that D-VTd is a valid treatment option for NDMM patients irrespective of transplant eligibility